{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:55:12Z","timestamp":1778547312983,"version":"3.51.4"},"reference-count":119,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm. Pat. Analyst"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.4155\/ppa.13.47","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T16:11:55Z","timestamp":1377187915000},"page":"647-663","source":"Crossref","is-referenced-by-count":51,"title":["Inhaled Antibiotics to Treat Lung Infection"],"prefix":"10.1080","volume":"2","author":[{"given":"David","family":"Cipolla","sequence":"first","affiliation":[{"name":"Department of Pharmacy\rPharmacy & Bank Building A15\rThe University of Sydney\rNSW\r2006\rAustralia"},{"name":"Aradigm Corp\r3929 Point Eden Way\rHayward\rCA\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hak-Kim","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy\rPharmacy & Bank Building A15\rThe University of Sydney\rNSW\r2006\rAustralia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,8,22]]},"reference":[{"key":"e_1_3_3_3_1_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-32"},{"key":"e_1_3_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.748034"},{"key":"e_1_3_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.660480"},{"key":"e_1_3_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161212799315975"},{"key":"e_1_3_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001634"},{"key":"e_1_3_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.676039"},{"key":"e_1_3_3_3_7_1","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.","author":"Assael BM","year":"2012","unstructured":"Assael BM , PresslerT, BiltonDet al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J. Cyst. Fibros. (2012).","journal-title":"J. Cyst. Fibros."},{"key":"e_1_3_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21315"},{"key":"e_1_3_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/ers.11.56"},{"key":"e_1_3_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.4187\/aarc0537"},{"key":"e_1_3_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.03.010"},{"key":"e_1_3_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.674500"},{"key":"e_1_3_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425240903110710"},{"key":"e_1_3_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(11)70022-1"},{"key":"e_1_3_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2011.0911"},{"key":"e_1_3_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.10.004"},{"key":"e_1_3_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/JB.183.23.6746-6751.2001"},{"key":"e_1_3_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn059"},{"key":"e_1_3_3_3_19_1","unstructured":"Bruinenberg P BlanchardJD CipollaDC DaytonF MudumbaS GondaI. Inhaled liposomal ciprofloxacin: once a day management of respiratory infections. In: Respiratory Drug Delivery 2010. Dalby RN Byron PR Peart J Suman JD Farr SJ Young PM (Eds). Davis Healthcare International Publishing LLC. River Grove IL USA 73\u201381 (2010)."},{"key":"e_1_3_3_3_20_1","unstructured":"Cipolla D RedelmeierT EastmanS BruinenbergP and Gonda I. Liposomes niosomes and proniosomes \u2013 a critical update of their (commercial) development as inhaled products. In: Respiratory Drug Delivery Europe 2011. Dalby RN Byron PR Peart J Suman JD Farr SJ Young PM (Eds). Davis Healthcare International Publishing LLC. River Grove IL USA 41\u201354 (2011)."},{"key":"e_1_3_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2007.0652"},{"key":"e_1_3_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2012.03.005"},{"key":"e_1_3_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl"},{"key":"e_1_3_3_3_24_1","first-page":"1361","volume":"129","author":"O\u2018Donnell A","year":"2009","unstructured":"O\u2018Donnell A , SwarnakarL, Yashina et al. A placebo controlled study of liposomal amikacin for inhalation (ARIKACE\u2122) nebulized once-daily in the treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa lung infection. ERS Ann. Conf.129, 1361 (2009).","journal-title":"ERS Ann. Conf."},{"key":"e_1_3_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-3659(93)90180-D"},{"key":"e_1_3_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01893.x"},{"key":"e_1_3_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1288"},{"key":"e_1_3_3_3_28_1","unstructured":"Hamblin KA BlanchardJD DaviesC HardingSV SimpsonAJH. Efficacy of inhaled liposome-encapsulated ciprofloxacin against Yersinia pestis. Presented at: 19th Congress of the International Society of Aerosols in Medicine. Chapel Hill NC USA 6\u201310 April 2013."},{"key":"e_1_3_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2011.05.012"},{"key":"e_1_3_3_3_30_1","first-page":"1","article-title":"Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: a systematic review of randomised controlled trials.","author":"Maiz L","year":"2013","unstructured":"Maiz L , GironRM, OlveiraCet al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: a systematic review of randomised controlled trials. Expert Opin. Pharmacother. 1\u201314 (2013).","journal-title":"Expert Opin. Pharmacother."},{"key":"e_1_3_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddstr.2011.07.001"},{"key":"e_1_3_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.10.54"},{"key":"e_1_3_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2013.783565"},{"key":"e_1_3_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21521"},{"issue":"1","key":"e_1_3_3_3_35_1","first-page":"101","article-title":"Efficacy of amikacin and ciprofloxacin against clinical isolates of Mycobacterium tuberculosis.","volume":"22","author":"Satti M","year":"2010","unstructured":"Satti M , FaqirF, SattarAet al. Efficacy of amikacin and ciprofloxacin against clinical isolates of Mycobacterium tuberculosis. J. Ayub. Med. Coll. Abbottabad 22(1), 101\u2013103 (2010).","journal-title":"J. Ayub. Med. Coll. Abbottabad"},{"key":"e_1_3_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00872-08"},{"key":"e_1_3_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde.13.71"},{"key":"e_1_3_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1586\/ers.12.39"},{"key":"e_1_3_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015924124180"},{"key":"e_1_3_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/10611869408996819"},{"key":"e_1_3_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201301-0184UP"},{"key":"e_1_3_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201105-0924OC"},{"key":"e_1_3_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1586\/ers.10.48"},{"key":"e_1_3_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2011.02.007"},{"key":"e_1_3_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q653"},{"key":"e_1_3_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp100624"},{"key":"e_1_3_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S11181"},{"key":"e_1_3_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01744-10"},{"key":"e_1_3_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201008-1293OC"},{"key":"e_1_3_3_3_50_1","first-page":"A3037","article-title":"A Phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (MP-376) administered for 5 days every 28 days to prevent acute exacerbations in high risk COPD patients.","author":"Sethi S","year":"2012","unstructured":"Sethi S , RennardS, MiravitllesMet al. A Phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (MP-376) administered for 5 days every 28 days to prevent acute exacerbations in high risk COPD patients. Am. J. Resp. Crit. Care Med. A3037 (2012).","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"e_1_3_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2012.48.5.1789474"},{"key":"e_1_3_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00071312"},{"key":"e_1_3_3_3_53_1","unstructured":"Yim D BlanchardJD MudumbaSet al. The development of inhaled liposome-encapsulated ciprofloxacin to treat cystic fibrosis. In: Respiratory Drug Delivery 2006. Dalby RN Byron PR Peart J Suman JD Farr SJ Young PM (Eds). Davis Healthcare Int\u2018l Publishing IL USA 425\u2013428 (2006)."},{"key":"e_1_3_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0827-0"},{"key":"e_1_3_3_3_55_1","unstructured":"Cipolla D WuH ChanJ Chan H-K Gonda I. Liposomal ciprofloxacin for inhalation retains integrity following nebulization. Proceedings of Respiratory Drug Delivery Europe 2013. Dalby RN Byron PR Peart J Suman JD Farr SJ Young PM. Berlin Germany 21\u201324 May 2013 237\u2013242 (2013)."},{"key":"e_1_3_3_3_56_1","unstructured":"Cipolla DC DaytonF FulzeleSet al. Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance. In: Respiratory Drug Delivery 2010. Dalby RN Byron PR Peart J Suman JD Farr SJ Young PM (Eds). Orlando FL USA 25\u201329 April 2010 409\u2013414 (2010)."},{"key":"e_1_3_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-009-9148-6"},{"key":"e_1_3_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30783"},{"key":"e_1_3_3_4_2_1","unstructured":"Pathogenesis: US5508269 (1996)."},{"key":"e_1_3_3_4_3_1","unstructured":"Chiesi Farmaceutici S.p.A.: US6987094 (2006)."},{"key":"e_1_3_3_4_4_1","unstructured":"Chiesi Farmaceutici S.p.A.: US7696178 (2010)."},{"key":"e_1_3_3_4_5_1","unstructured":"Chiesi Farmaceutici S.p.A.: US7939502 (2011)."},{"key":"e_1_3_3_4_6_1","unstructured":"Chiesi Farmaceutici S.p.A.: US8168598 (2012)."},{"key":"e_1_3_3_4_7_1","unstructured":"Inhale Therapeutic Systems: US7097827 (2006)."},{"key":"e_1_3_3_4_8_1","unstructured":"Nektar Therapeutics: US7368102 (2008)."},{"key":"e_1_3_3_4_9_1","unstructured":"Unassigned US7442388 (2008)."},{"key":"e_1_3_3_4_10_1","unstructured":"Novartis AG: US8349294 (2013)."},{"key":"e_1_3_3_4_11_1","unstructured":"Novartis AG: US7516741 (2009)."},{"key":"e_1_3_3_4_12_1","unstructured":"Novartis Pharma AG: US7559325 (2009)."},{"key":"e_1_3_3_4_13_1","unstructured":"Novartis AG: US8069851 (2011)."},{"key":"e_1_3_3_4_14_1","unstructured":"Pathogenesis: US6083922 (2000)."},{"key":"e_1_3_3_4_15_1","unstructured":"Chiron: US6890907 (2005)."},{"key":"e_1_3_3_4_16_1","unstructured":"Chiron: US6387886 (2002)."},{"key":"e_1_3_3_4_17_1","unstructured":"Novartis: US7825095 (2010)."},{"key":"e_1_3_3_4_18_1","unstructured":"Transave: US7544369 (2009)."},{"key":"e_1_3_3_4_19_1","unstructured":"Transave: US7718189 (2010)."},{"key":"e_1_3_3_4_20_1","unstructured":"Transave: US7879351 (2011)."},{"key":"e_1_3_3_4_21_1","unstructured":"Insmed: US8226975 (2012)."},{"key":"e_1_3_3_4_22_1","unstructured":"Aerogen: US6968840 (2005)."},{"key":"e_1_3_3_4_23_1","unstructured":"Aerogen: US7331339 (2008)."},{"key":"e_1_3_3_4_24_1","unstructured":"Novartis: US7748377 (2010)."},{"key":"e_1_3_3_4_25_1","unstructured":"Novartis: US8375947 (2013)."},{"key":"e_1_3_3_4_26_1","unstructured":"Cardeas Pharma Inc.: WO2013010041 (2013)."},{"key":"e_1_3_3_4_27_1","unstructured":"Gilead Sciences Inc.: US7943118 (2011)."},{"key":"e_1_3_3_4_28_1","unstructured":"Gilead Sciences Inc.: US8361444 (2013)."},{"key":"e_1_3_3_4_29_1","unstructured":"Gilead Sciences Inc.: US8409549 (2013)."},{"key":"e_1_3_3_4_30_1","unstructured":"Corus Pharma Inc.: US7208141 (2007)."},{"key":"e_1_3_3_4_31_1","unstructured":"Corus Pharma Inc.: US7214364 (2007)."},{"key":"e_1_3_3_4_32_1","unstructured":"Corus Pharma Inc.: US7427633 (2008)."},{"key":"e_1_3_3_4_33_1","unstructured":"Gilead Sciences Inc.: US8399496 (2013)."},{"key":"e_1_3_3_4_34_1","unstructured":"Mpex: US7838532 (2010)."},{"key":"e_1_3_3_4_35_1","unstructured":"Mpex: US8357696 (2013)."},{"key":"e_1_3_3_4_36_1","unstructured":"Integrated Research Technology LLC: US7067500 (2006)."},{"key":"e_1_3_3_4_37_1","unstructured":"Bayer: US8034817 (2011)."},{"key":"e_1_3_3_4_38_1","unstructured":"Minister of National Defence of Her Majesty\u2018s Canadian Government: US5968548 (1999)."},{"key":"e_1_3_3_4_39_1","unstructured":"Aradigm Corp.: US8071127 (2011)."},{"key":"e_1_3_3_4_40_1","unstructured":"Aradigm Corp.: US8119156 (2012)."},{"key":"e_1_3_3_4_41_1","unstructured":"Aradigm Corp.: US8268347 (2012)."},{"key":"e_1_3_3_4_42_1","unstructured":"Aradigm Corp.: US8414915 (2013)."},{"key":"e_1_3_3_4_43_1","unstructured":"Savara Pharmaceuticals: WO2012159103 (2012)."},{"key":"e_1_3_3_4_44_1","unstructured":"University of Iowa Research Foundation: US5997912 (1999)."},{"key":"e_1_3_3_4_45_1","unstructured":"University of Iowa Research Foundation: US6203822 (2001)."},{"key":"e_1_3_3_4_46_1","unstructured":"Gilead Sciences Inc.: US7973029 (2013)."},{"key":"e_1_3_3_4_47_1","unstructured":"Pathogenesis: US5767068 (1998)."},{"key":"e_1_3_3_5_2_1","unstructured":"US FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. www.accessdata.fda.gov\/scripts\/cder\/ob\/default.cfm"},{"key":"e_1_3_3_5_3_1","unstructured":"US Patent and Trademark Office. www.uspto.gov"},{"key":"e_1_3_3_5_4_1","unstructured":"Insmed Company website describing Arikace for use in NTM. www.insmed.com\/product-candidates\/arikace-for-patients-with-ntm-lung-infections (Accessed 30April2013)"},{"key":"e_1_3_3_5_5_1","unstructured":"Insmed Company website describing Arikace for use in CF. www.insmed.com\/product-candidates\/arikace-for-cf-patients-with-pseudomonas-lung-infections (Accessed 30April2013)"},{"key":"e_1_3_3_5_6_1","unstructured":"The US FDA\u2018s website on clinical trials: www.clinicaltrials.gov (Accessed 21June2013)"},{"key":"e_1_3_3_5_7_1","unstructured":"Insmed Company website October 10 2011 press release. http:\/\/investor.insmed.com\/releasedetail.cfm?ReleaseID=613070 (Accessed 14June2013)"},{"key":"e_1_3_3_5_8_1","unstructured":"Insmed Company website May 7 2012 press release. http:\/\/investor.insmed.com\/releasedetail.cfm?ReleaseID=670796 (Accessed 14June2013)"},{"key":"e_1_3_3_5_9_1","unstructured":"ClinicalTrials Database: NCT01799993. www.clinicaltrials.gov\/ct2\/show\/NCT01799993?term=bayer+amikacin&rank=1 (Accessed 30April2013)"},{"key":"e_1_3_3_5_10_1","unstructured":"Insmed Company website August 1 2011 press release. http:\/\/investor.insmed.com\/releasedetail.cfm?ReleaseID=595630 (Accessed 14June2013)"},{"key":"e_1_3_3_5_11_1","unstructured":"A randomized double-blind placebo-controlled dose\u2013escalation Phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow Inline Nebulizer System in mechanically ventilated patients. http:\/\/cardeaspharma.com\/news\/publications (Accessed 20June2013)"},{"key":"e_1_3_3_5_12_1","unstructured":"Cayston (aztreonam) inhalation solution label. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050814s007lbl.pdf (Accessed 30April2013)"},{"key":"e_1_3_3_5_13_1","unstructured":"Aptalis Press Release 7 January 2013. http:\/\/aptalispharma.mwnewsroom.com\/press-releases\/aptalis-pharma-inc-announces-results-of-phase-3--971086 (Accessed 30April2013)"},{"key":"e_1_3_3_5_14_1","unstructured":"Savara Press Release 18 April 2013. http:\/\/savarapharma.com\/savara-pharmaceuticals-initiates-phase-2-clinical-trial-of-aerovanc-for-mrsa-lung-infection-in-cystic-fibrosis-patients (Accessed 30April2013)"},{"key":"e_1_3_3_5_15_1","unstructured":"Aridis Pharma web page describing Panaecin in CF. www.aridispharma.com\/panaecin.html (Accessed 20June2013)"},{"key":"e_1_3_3_5_16_1","unstructured":"Global Inhaled Antibiotic Market 2011\u20132015 Infinity Research Ltd. www.researchandmarkets.com\/research\/22031a59\/global_inhaled_ant (Accessed 30April2013)"}],"updated-by":[{"DOI":"10.4155\/ppa.13.80","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,12,20]],"date-time":"2013-12-20T00:00:00Z","timestamp":1387497600000}}],"container-title":["Pharmaceutical Patent Analyst"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/ppa.13.47","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:53:47Z","timestamp":1715986427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/ppa.13.47"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,22]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.4155\/ppa.13.47"],"URL":"https:\/\/doi.org\/10.4155\/ppa.13.47","relation":{},"ISSN":["2046-8954","2046-8962"],"issn-type":[{"value":"2046-8954","type":"print"},{"value":"2046-8962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,22]]}}}